| DDS(s) |
Drug-delivery system(s) |
| BBB |
Blood–brain barrier |
| CNS |
Central nervous system |
| CMT, RMT and AMT |
Carrier-mediated, receptor-mediated and absorptive-mediated transcytosis |
| P-gp |
P-glycoprotein |
| WHO |
World Health Organization |
| GBM |
Glioblastoma multiforme |
| Tf, oTf and Lf |
serum-Transferrin, ovo-Transferrin and Lactoferrin |
| TfR |
Transferrin receptor |
| EPR |
Enhanced permeability and retention |
| NP(s) |
Nanoparticle(s) |
| AuNP(s) |
Gold nanoparticle(s) |
| MNP(s) |
Magnetic nanoparticle(s) |
| MRI |
Magnetic resonance imaging |
| PM(s) |
Polymeric micelle(s) |
| SNP(s) |
Polymeric solid nanoparticle(s) |
| Apo-A1 and Apo-E |
Apolipoprotein A1 and Apolipoprotein E |
| LbL assembly |
Layer-by-layer assembly |
| LA and GA |
Lactic acid and Glycolic acid |
| Abbreviated Chemicals: |
| FTIC |
Fluorescein isothiocyanate |
| IO |
Iron oxide |
| PS-PAA |
Poly(styrene)-poly(acrylic acid) |
| PEG-PLA |
Poly(ethylene)glycol-poly(lactic acid) |
| PEG-DSPE |
Distearyl-sn-glycero-3-phosphoethanolamine-N-methoxy poly |
|
|
(ethylene glycol) |
| PEG-PLA |
Poly(ethylene glycol)-poly(lactic acid) |
| PEG-PLGA |
Poly(ethylene glycol)-poly(lactic-co-glycolic acid) |
| DPX |
Dapoxetine |
| PAMAM |
Polyamidoamine |
| IL-13R2 |
Interleukin-13-receptor-2 |
| EDC |
N-Ethyl-N-(3-dimethylaminopropyl)carbodiimide hydrochloride |
| NHS |
N-hydroxysuccinimide |
| PLGA |
Poly(lactic-co-glycolic acid) |
| PEG |
Poly(ethylene(glycol |
| BSA |
Bovine serum albumin |
| FR
|
Folate receptor alpha |
| Cur |
Curcumin |
| g7 |
Gly-l-Phe-D-Thr-Gly-l-Phe-l-Leu-LSer(O--D-Glucose)-CONH
|
| TMC |
Trimethylated chitosan |
| PEP |
PLGA-PEG-PLGA |